X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Dishman Pharma with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs MYLAN (US) - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DISHMAN PHARMA   MYLAN
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
MYLAN
Dec-14
DISHMAN PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs3743,802-   
Low Rs1292,679-   
Sales per share (Unadj.) Rs197.81,301.5-  
Earnings per share (Unadj.) Rs21.2156.8-  
Cash flow per share (Unadj.) Rs34.7252.4-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.9647.0-  
Shares outstanding (eoy) m80.69378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x1.32.5 51.1%   
Avg P/E ratio x11.920.7 57.4%  
P/CF ratio (eoy) x7.212.8 56.4%  
Price / Book Value ratio x1.45.0 27.9%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,3061,226,120 1.7%   
No. of employees `0000.825.0 3.3%   
Total wages/salary Rs m5,3550-   
Avg. sales/employee Rs Th19,252.719,698.4 97.7%   
Avg. wages/employee Rs Th6,459.50-   
Avg. net profit/employee Rs Th2,064.12,373.0 87.0%   
INCOME DATA
Net Sales Rs m15,961492,459 3.2%  
Other income Rs m265-2,871 -9.2%   
Total revenues Rs m16,226489,588 3.3%   
Gross profit Rs m4,103122,477 3.4%  
Depreciation Rs m1,09136,169 3.0%   
Interest Rs m94421,242 4.4%   
Profit before tax Rs m2,33462,195 3.8%   
Minority Interest Rs m0-255 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6242,615 23.8%   
Profit after tax Rs m1,71159,325 2.9%  
Gross profit margin %25.724.9 103.4%  
Effective tax rate %26.74.2 635.5%   
Net profit margin %10.712.0 89.0%  
BALANCE SHEET DATA
Current assets Rs m11,018432,936 2.5%   
Current liabilities Rs m9,517338,470 2.8%   
Net working cap to sales %9.419.2 49.0%  
Current ratio x1.21.3 90.5%  
Inventory Days Days11078 141.5%  
Debtors Days Days35107 32.5%  
Net fixed assets Rs m16,304113,929 14.3%   
Share capital Rs m16117,415 0.9%   
"Free" reserves Rs m12,9070-   
Net worth Rs m14,516244,801 5.9%   
Long term debt Rs m4,189365,708 1.1%   
Total assets Rs m29,805986,034 3.0%  
Interest coverage x3.53.9 88.4%   
Debt to equity ratio x0.31.5 19.3%  
Sales to assets ratio x0.50.5 107.2%   
Return on assets %8.98.2 109.0%  
Return on equity %11.824.2 48.6%  
Return on capital %17.513.6 128.7%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Net fx Rs m4,2550-   
CASH FLOW
From Operations Rs m2,78664,734 4.3%  
From Investments Rs m-1,529-51,051 3.0%  
From Financial Activity Rs m-941-17,057 5.5%  
Net Cashflow Rs m316-3,374 -9.4%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 63.79 Rs / USD

Compare DISHMAN PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare DISHMAN PHARMA With: JUBILANT LIFE SCIENCES  MERCK LTD  ALEMBIC PHARMA  SANOFI INDIA  ORCHID PHARMA LTD  



Today's Market

Sensex Trades on a Volatile Note; Airtel, Idea Down by 5%(01:30 pm)

After opening the day in green share markets in India witnessed choppy trading activity and are presently trading above the dotted line.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS